Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 3, 2005 (13 weeks)
Business Overview: Illumina develops and markets tools for large-scale genetic analysis, including oligonucleotides, genotyping systems (BeadLab, BeadStation), and gene expression systems. The company operates in a single segment and relies heavily on research and development to commercialize new technologies.
Key Financial Metrics
| Metric (in thousands) | Q1 2005 | Q1 2004 |
|---|---|---|
| Total Revenue | $15,148 | $10,803 |
| Net Loss | $(1,235) | $(3,931) |
| Loss per Share (Basic/Diluted) | $(0.03) | $(0.12) |
| Cash and Cash Equivalents | $52,953 | $8,740 |
| Total Assets | $93,780 | $94,907 |
| Stockholders' Equity | $72,422 | $72,262 |
| Operating Cash Flow | $(3,325) | $(4,710) |
Margins:
- Product Gross Margin: 68% (down from 71% in Q1 2004).
- Service Gross Margin: 75% (down from 79% in Q1 2004).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 40% to $15.1 million, driven by a 36% increase in product revenue (primarily BeadStation sales) and a 134% increase in service revenue (SNP genotyping contracts and HapMap project completion).
- Expense Reduction: Net loss improved significantly to $1.2 million from $3.9 million. This was aided by the absence of a $189,000 litigation interest charge recorded in the prior year and a reduction in stock-based compensation amortization from $318,000 to $57,000.
- Liquidity: Cash and cash equivalents increased to $53.0 million from $8.7 million in the prior year period, bolstered by a $15.5 million net cash inflow from a sale-leaseback transaction in late 2004 and proceeds from stock issuance.
- Debt: The company paid off its $26 million mortgage in August 2004 via the sale-leaseback transaction. As of April 3, 2005, there is no long-term debt listed on the balance sheet.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management expects to continue incurring net losses through most of 2005 due to substantial R&D and sales infrastructure costs.
- The company anticipates that the completion of the International HapMap Project (which contributed 16% of Q1 2005 revenue) will be offset by the commercial launch of whole-genome genotyping and gene expression arrays.
- Cash resources are deemed sufficient to fund operations for at least 24 months.
Recent Acquisitions:
- On April 8, 2005, Illumina acquired CyVera Corporation for $17.5 million (stock and liability assumption). A significant portion of the purchase price is expected to be allocated to in-process R&D and charged to earnings in Q2 2005.
Risks and Contingencies:
- Litigation: Affymetrix, Inc. filed a patent infringement suit in July 2004 alleging infringement of six patents. No trial date is set, but an unfavorable outcome could materially harm the business.
- Accounting Changes: Adoption of SFAS 123R (Share-Based Payment) is expected in 2006, which will result in significant non-cash charges to operating expenses.
- Personnel: The CFO, Timothy Kish, resigned effective April 29, 2005. Christian Henry was hired to replace him, starting in early June 2005.
Investor Verification Checklist
- CyVera Acquisition Impact: Verify the final accounting treatment of the CyVera acquisition, specifically the amount allocated to in-process R&D that will impact Q2 2005 earnings.
- Post-HapMap Revenue: Monitor Q2 and Q3 2005 revenue trends to confirm that commercial product launches are successfully offsetting the loss of HapMap grant funding.
- Affymetrix Litigation: Track developments in the patent infringement lawsuit, as an injunction or damages award could be material.
- Stock-Based Compensation: Review the impact of the upcoming SFAS 123R adoption on future reported operating expenses and net loss.
- Product Mix Margins: Analyze the shift in product mix (BeadStation vs. oligos) to understand the pressure on gross margins.